---
layout: default
title: Ramucirumab
parent: 僅模型預測 (L5)
nav_order: 1108
evidence_level: L5
indication_count: 10
---

# Ramucirumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ramucirumab: From Unspecified Original Oncology Indication to Uterine Ligament Adenocarcinoma

## One-Sentence Summary

Ramucirumab is a VEGFR2-targeting monoclonal antibody; its original approved indication is not documented in this evidence pack.
The TxGNN model predicts it may be effective for **Uterine Ligament Adenocarcinoma** (and 9 closely related rare gynecologic carcinoma subtypes),
but there are currently **0 clinical trials** and **0 publications** supporting this specific direction — the prediction rests solely on network-based inference.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in this evidence pack |
| Predicted New Indication | Uterine Ligament Adenocarcinoma |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is flagged as a data gap in this evidence pack (DG002, High severity). However, the repurposing rationale supplied with the prediction indicates that Ramucirumab is a **VEGFR2 monoclonal antibody** that inhibits tumor angiogenesis.

The original indication is not recorded here, so no direct comparison between the original and predicted indications can be made from this evidence pack alone. Mechanistically, the rationale draws an analogy to the "class effect" seen with other anti-angiogenic agents (e.g., bevacizumab in the GOG-240 trial) in gynecologic malignancies such as cervical cancer — suggesting that VEGFR2 blockade has a plausible theoretical basis across gynecologic adenocarcinoma subtypes. This is a mechanism-level inference, not a validated finding for Ramucirumab specifically.

All ten predicted indications in this evidence pack are rare cervical/uterine ligament carcinoma subtypes with near-identical TxGNN scores (~99.9%), and every one is explicitly noted as having **no direct clinical or literature evidence** — the mechanistic argument is theoretical only.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Additional Predicted Indications (Rank 2–10)

| Rank | Disease | TxGNN Score |
|------|---------|-------------|
| 2 | Endocervical carcinoma | 99.95% |
| 3 | Adenoid cystic carcinoma of the cervix uteri | 99.95% |
| 4 | Uterine ligament serous adenocarcinoma | 99.94% |
| 5 | Signet ring cell variant cervical mucinous adenocarcinoma | 99.94% |
| 6 | Cervical adenosquamous carcinoma, glassy cell variant | 99.94% |
| 7 | Uterine ligament endometrioid adenocarcinoma | 99.94% |
| 8 | Uterine ligament clear cell adenocarcinoma | 99.94% |
| 9 | Uterine ligament mucinous adenocarcinoma | 99.94% |
| 10 | Intestinal variant cervical mucinous adenocarcinoma | 99.94% |

All entries share the same evidence status: L5, S0, Hold — no clinical trials or literature identified for any of them.

---

## Cytotoxicity

*(Included because the drug targets VEGFR2 as an anti-angiogenic agent, and all predicted indications are carcinomas.)*

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (VEGFR2-targeted anti-angiogenic monoclonal antibody) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: TFDA/FDA label warnings and contraindications are flagged as a Blocking data gap — DG001 — in this evidence pack and could not be evaluated.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All ten predicted indications rely exclusively on TxGNN model output (L5) with zero supporting clinical trials or literature, and a Blocking data gap (missing label warnings/contraindications) prevents even initial safety screening.

**To proceed, the following is needed:**
- TFDA/FDA package insert warnings and contraindications (DG001, Blocking)
- Confirmed mechanism of action data from DrugBank (DG002, High)
- Original approved indication(s) for baseline mechanistic comparison
- Any preclinical or case-level evidence specific to Ramucirumab in gynecologic adenocarcinoma subtypes before advancing beyond S0
- US market/licensing status verification, given the current record shows 0 licenses
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

